Valuation: GlobeImmune Inc

Market Cap 1.67M 1.46M 1.38M 1.26M 2.35M 160M 2.37M 16.53M 6.41M 81.46M 6.26M 6.13M 264M P/E 2014
-0.94x
P/E 2015 -8.04x
Enterprise Value -8.23M -7.23M -6.79M -6.21M -11.6M -789M -11.69M -81.59M -31.63M -402M -30.92M -30.24M -1.3B EV / Sales 2014
4.5x
EV / Sales 2015 1.91x
Free-Float
100%
Yield 2014 *
-
Yield 2015 -
Change 5-day change 1-year change 3-year change Capi.($)
+27.31%-24.56% - - 575
+0.06%+6.49%+60.29%+111.13% 74.27B
-2.29%-1.51%+33.30%+75.07% 61.21B
-0.57%+5.19%+31.88%+20.59% 27.55B
-2.05%-3.46%-18.60%+352.20% 26.38B
-2.39%+2.74%+0.19%-5.91% 25.34B
+0.57%+3.66%+25.59%-9.37% 20.84B
-2.15%+2.73%-4.86%+508.08% 14.94B
+1.29%-2.49%+152.11%+333.06% 15.17B
-2.44%-0.09%+42.50%+164.11% 14.41B
Average +1.80%+2.36%+35.82%+172.11% 31.12B
Weighted average by Cap. -1.02%+2.32%+36.73%+133.42%

Financials

2014 2015
Net sales 5.97M 5.24M 4.92M 4.5M 8.41M 572M 8.47M 59.13M 22.92M 291M 22.41M 21.91M 945M 6.46M 5.67M 5.33M 4.87M 9.1M 619M 9.17M 64M 24.81M 315M 24.25M 23.72M 1.02B
Net income -16.26M -14.27M -13.42M -12.27M -22.92M -1.56B -23.09M -161M -62.47M -794M -61.06M -59.73M -2.57B -2.77M -2.43M -2.28M -2.09M -3.9M -265M -3.93M -27.42M -10.63M -135M -10.39M -10.16M -438M
Net Debt -16.81M -14.76M -13.87M -12.68M -23.7M -1.61B -23.87M -167M -64.59M -821M -63.14M -61.75M -2.66B -9.9M -8.69M -8.17M -7.47M -13.96M -948M -14.06M -98.12M -38.04M -484M -37.18M -36.37M -1.57B
Logo GlobeImmune Inc
GlobeImmune Inc. is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s Tarmogen platform activates the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells in contrast to traditional vaccines, which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. It has over two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company's oncology product candidates include GI-6301, GI-6207 and GI-4000. The Company's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.
Employees
-